bwge2019 has ended

Create Your Own Event

bwge2019

Belgian Week of Gastroenterology 2019

13:15 CET

Satellite Symposium TAKEDA Room LIJN

14:00 CET

Invited Lecture: Genetics of IBD Disease Severity Room LIJNJames Lee

14:25 CET

A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease Room LIJNBram Verstockt

14:35 CET

An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease Room LIJNBram Verstockt

14:45 CET

Genetic predisposition and thiopurine-induced pancreatitis in inflammatory bowel disease patients Room LIJNGuillaume Burnet

14:55 CET

Upregulation of IL17-related pathways in affected colon from ulcerative colitis compared to Crohn’s disease Room LIJNSare Verstockt

15:05 CET

Invited Lecture: 2018 Microbiota in the Healthy and IBD Room LIJNJeroen Raes

15:30 CET

Coffee break Room LIJN

16:00 CET

Molecular changes in non-inflamed terminal ileum in patients with ulcerative colitis Room LIJNHo-Su Lee

16:10 CET

Hepatocyte growth factor and MET in ulcerative colitis, novel drug targets impairing neutrophil recruitment? Room LIJNMichelle Stakenborg

16:20 CET

Organoids derived of inflammatory intestinal biopsies in ulcerative colitis patients lose their inflammatory transcriptional signature over time Room LIJNKaline Arnauts

16:30 CET

Invited Lecture: How T cells harm and protect the intestinal mucosa in IBD Room LIJNMathieu Allez

17:00 CET

Satellite Symposium PFIZER : Practical experience with XELJANZ® (tofacitinib) in ulcerative colitis Room LIJNSéverine Vermeire

18:00 CET

General Assembly IBD Room LIJN

08:15 CET

Breakfast Symposium BIOGEN Room LIJN

09:00 CET

Invited Lecture: HSCT in refractory IBD and primary immunodeficiency disorders Room LIJNMathieu Allez

09:35 CET

TREM1, the first anti-TNF specific biomarker guiding therapeutic decision Room LIJNBram Verstockt

09:45 CET

Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single centre experience Room LIJNBram Verstockt

09:55 CET

Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF or conventional therapy. Room LIJNAnnick Moens

10:05 CET

Long-term clinical efficacy of Ustekinumab in refractory Crohn’s disease: a multi-centre Belgian cohort study Room LIJNClaire Liefferinckx

10:15 CET

Invited Lecture: Trough levels, drug- sensitive/tolerant ADA: Et Après… Remaining questions and Possible answers Room LIJNXavier Roblin

11:00 CET

Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease Room LIJNErwin Dreesen

11:10 CET

A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis Room LIJNwannee kantasiripitak

11:20 CET

Significant reduction of admission time at the IBD infusion unit by an e-health pre-admission assessment and order system for intravenous therapy. Room LIJNEveline Hoefkens

11:30 CET

POSTOPERATIVE ENDOSCOPIC AND CLINICAL RECURRENCE AFTER ILEOCOLONIC RESECTION IN PATIENTS WITH CROHN’S DISEASE CANNOT BE PREVENTED WITH HIGH DOSE VITAMIN D Room LIJNMarjolijn Duijvestein

11:40 CET

Invited Lecture: Improving Quality of Care of Endoscopy in IBD: Scoring systems and Chromoendoscopy, How I do it? Peter Bossuyt Room LIJN

12:00 CET

Satellite Symposium JANSSEN-CILAG : Targeting IL-23/-12 in Crohn's disease: experience from across the border Room LIJNMarco Daperno